Form 4: Zymeworks Inc. Grants Stock Options to Troy Cox

Zymeworks Inc. has granted stock options to Troy Cox, exercisable at $13.06 per share, vesting after the next annual general meeting.

Summary

• Zymeworks Inc. granted stock options to Troy Cox on December 10, 2024.
• The options allow Mr. Cox to purchase 31,000 shares of common stock at a price of $13.06 per share.
• The options vest on the date of the next annual general meeting following the grant date.
• The options expire on December 9, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate action of granting stock options, which is generally viewed positively as it aligns employee interests with company performance. There is no indication of any negative sentiment.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation in the biotech industry, often used to align the interests of employees with those of shareholders.
• The vesting schedule of options is typical, often tied to employment milestones or company performance.
• Companies like Amgen, Regeneron, and Gilead also use stock options as part of their compensation packages.

Stakeholder Impact

• The stock option grant may have a positive impact on employee morale and retention.
• Shareholders may view this as a positive step in aligning management's interests with the company's long-term success.

Next Steps

• The stock options will vest after the next annual general meeting.

Key Dates

Keywords

stock options, equity compensation, Zymeworks Inc., Troy Cox, vesting, common stock